DNER and glioblastoma: One BET inhibitor that has been studied with GBM is JQ1. Cheng et al. assessed JQ1 in a panel of genetically heterogeneous GBM samples. They used ex vivo cultures derived from primary GBM xenograft lines and orthotopic GBM tumors to test in vivo efficacy.